Trial Profile
A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Sevirumab (Primary)
- Indications Cytomegalovirus retinitis
- Focus Adverse reactions
- Sponsors Sandoz
- 21 Jul 2016 New trial record